Sandbox ID Cardiovascular

Jump to navigation Jump to search
  • Native valve endocarditis caused by highly penicillin-susceptible viridans group streptococci and Streptococcus bovis (MIC ≤ 0.12 μg/mL)
  • Preferred regimen: Penicillin G 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks.
  • Alternative regimen (1): (Penicillin G 12–18 million U/24 h IV either continuously or in 6 equally divided doses for 2 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 2 weeks) AND Gentamicin 3 mg/kg per 24h IV/IM in 1 dose for 2 weeks.
  • Alternative regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 4 weeks.
  • Pediatric dose: Penicillin G 200,000 U/kg per 24 h IV in 4–6 equally divided doses; Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses; Vancomycin 40 mg/kg per 24 h IV in 2–3 equally divided doses.
  • Native valve endocarditis caused by relatively penicillin-resistant viridans group streptococci and Streptococcus bovis (MIC > 0.12 to ≤ 0.5 μg/mL)
  • Preferred regimen (1): (Penicillin G 24 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks) AND Gentamicin 3 mg/kg per 24h IV/IM in 1 dose for 2 weeks.
  • Preferred regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 4 weeks.
  • Pediatric dose: Penicillin G 200,000 U/kg per 24 h IV in 4–6 equally divided doses; Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses; Vancomycin 40 mg/kg per 24 h IV in 2–3 equally divided doses.
  • Prosthetic valve endocarditis caused by highly penicillin-susceptible viridans group streptococci and Streptococcus bovis (MIC ≤ 0.12 μg/mL)
  • Preferred regimen (1): (Penicillin G 24 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 6 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 6 weeks) ± Gentamicin 3 mg/kg per 24h IV/IM in 1 dose for 2 weeks.
  • Preferred regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 6 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg per 24 h IV in 4–6 equally divided doses; Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses; Vancomycin 40 mg/kg per 24 h IV in 2–3 equally divided doses.
  • Prosthetic valve endocarditis caused by relatively penicillin-resistant viridans group streptococci and Streptococcus bovis (MIC > 0.12 μg/mL)
  • Preferred regimen (1): (Penicillin G 24 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 6 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 6 weeks) AND Gentamicin 3 mg/kg per 24h IV/IM in 1 dose for 2 weeks.
  • Preferred regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 6 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg per 24 h IV in 4–6 equally divided doses; Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses; Vancomycin 40 mg/kg per 24 h IV in 2–3 equally divided doses.
  • Native valve endocarditis caused by oxacillin-susceptible staphylococci
  • Preferred regimen (1): Nafcillin or Oxacillin 12 g/24 h IV in 4–6 equally divided doses for 6 wk ± Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses for 3–5 days.
  • Preferred regimen (2): Cefazolin 6 g/24 h IV in 3 equally divided doses 6 wk ± Gentamicin sulfate3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses for 3–5 days.
  • Pediatric dose: Nafcillin or Oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses; Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses; Cefazolin 100 mg/kg per 24 h IV in 3 equally divided doses; Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses.
  • Native valve endocarditis caused by oxacillin-resistant staphylococci
  • Preferred regimen: Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses for 6 weeks.
  • Pediatric dose: Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses.
  • Prosthetic valve endocarditis caused by oxacillin-susceptible staphylococci
  • Preferred regimen: Nafcillin or Oxacillin 12 g/24 h IV in 6 equally divided doses for ≥6 AND Rifampin 900 mg per 24 h IV/PO in 3 equally divided doses for ≥6 AND Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses for 2 weeks.
  • Pediatric dose: Nafcillin or Oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses; Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses; Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses.
  • Prosthetic valve endocarditis caused by oxacillin-resistant staphylococci
  • Preferred regimen: Vancomycin 30 mg/kg 24 h in 2 equally divided doses for ≥6 AND Rifampin 900 mg/24 h IV/PO in 3 equally divided doses ≥6 weeks AND Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses for 2 weeks.
  • Pediatric dose: Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses; Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses (up to adult dose); Gentamicin 3 mg/kg per 24 h IV or IM in 3 equally divided doses.
  • Endocarditis caused by enterococcal strains susceptible to penicillin, gentamicin, and vancomycin
  • Endocarditis caused by enterococcal strains susceptible to penicillin, streptomycin, and vancomycin and resistant to gentamicin
  • Preferred regimen : (Ampicillin sodium 12 g/24 h IV in 6 equally divided doses for 4–6 weeks OR Aqueous crystalline penicillin G sodium 24 million U/24 h IV continuously or in 6 equally divided doses for 4–6 weeks AND Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses for 4–6 weeks.
  • Alternative regimen : Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses for 6 weeks AND Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses for 6 weeks.
  • Pediatric dose: Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; Penicillin 300 000 U/kg per 24 h IV in 4–6 equally divided doses; Streptomycin 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses; Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses; Streptomycin 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses.
  • Endocarditis caused by enterococcal strains resistant to penicillin and susceptible to aminoglycoside and vancomycin
  • Regimen for β-Lactamase–producing strain
  • Regimen for Intrinsic penicillin resistance
  • Preferred regimen: Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses for 6 weeks AND Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses for 6 weeks.
  • Pediatric dose: Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses; Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses
  • Endocarditis caused by enterococcal strains resistant to penicillin, gentamicin, and vancomycin
  • Enterococcus faecium
  • Preferred regimen : [Linezolid]] 1200 mg/24 h IV/PO in 2 equally divided doses for ≥8 weeks OR Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses for 8weeks.
  • Enterococcus faecalis
  • Suspected Bartonella endocarditis
  • (table 14)
  • Documented Bartonella endocarditis
  • (table 14)
  • Culture-negative, native valve endocarditis
  • (table 14)
  • Culture-negative, prosthetic valve endocarditis (early, ≤ 1 year)
  • (table 14)
  • Culture-negative, prosthetic valve endocarditis (late, > 1 year)
  • (table 14)

  • Patients with atrioventricular heart block and/or myopericarditis associated with early Lyme disease
  • Preferred oral regimens: Amoxicillin 500 mg 3 times per day for 14 days OR Doxycycline 100 mg twice per day for 14 days OR Cefuroxime 500 mg twice per day for 14 days
  • Alternative oral regimens:
  • Preferred parenteral regimens:
  • Alternative parenteral regimens:
  • Pediatric dose:

  • Mycotic aneurysm

  • Implantable electronic device infections

  • Pericarditis
  • Bacterial pericarditis
  • Histoplasmosis
  • Extrapulmonary tuberculosis

  • Rheumatic fever

  • Cavernous sinus thrombosis

  • Intravenous line infections
  • Intravenous line infections, non-tunneled
  • Intravenous line infections, tunneled

  • Septic pelvic vein thrombophlebitis

  • Suppurative phlebitis

  • Ventricular-assist device infections

References

  1. Baddour, Larry M.; Wilson, Walter R.; Bayer, Arnold S.; Fowler, Vance G.; Bolger, Ann F.; Levison, Matthew E.; Ferrieri, Patricia; Gerber, Michael A.; Tani, Lloyd Y.; Gewitz, Michael H.; Tong, David C.; Steckelberg, James M.; Baltimore, Robert S.; Shulman, Stanford T.; Burns, Jane C.; Falace, Donald A.; Newburger, Jane W.; Pallasch, Thomas J.; Takahashi, Masato; Taubert, Kathryn A.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America (2005-06-14). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): –394-434. doi:10.1161/CIRCULATIONAHA.105.165564. ISSN 1524-4539. PMID 15956145.